APLS — Apellis Pharmaceuticals, Inc. Dilution Risk Tracker

Apellis Pharmaceuticals, Inc. (APLS) has a DilutionScore of 25/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 13, 2026.

Cash runway is a key watch item: APLS has approximately 15 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for APLS in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for APLS alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.